HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC
A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week…